الفهرس | Only 14 pages are availabe for public view |
Abstract A blood-innate viral infection known as chronic hepatitis C virus (HCV) affects millions of individuals worldwide and is a leading cause of death. Based on the variability of the genetic sequence, six HCV genotypes with several subtypes were identified. Direct-acting antiviral drug discovery and approval have recently improved HCV treatment (DAAs). A sustained virological response (SVR), which is undetectable HCV RNA twelve weeks (SVR12) or twenty-four weeks (SVR24) after treatment completion, is the main goal of treating hepatitis C viral infection. However, certain patients do not respond to therapy, including those with genotype 3 cirrhosis, those with resistance-associated substitutions (RAS), or those with poor treatment adherence linked to social impairments (homeless, psychiatric illnesses, injection drug use, alcoholism, etc.). As a result, the creation of fixed dose combinations (FDC) was started as a method to solve these issues. The majority of FDCs use the antiviral medications ledipasvir, valpatasvir, voxilaprevir, daclatasvir, and elbasvir in addition to sofosbuvir as the primary agent. A prodrug with direct antiviral activity is sofosbuvir. It works by impeding RNA polymerase, which thus prevents HCV from replicating its RNA. |